Galaxy Therapeutics Secures CE Mark for SEAL System
Milpitas, California, August 4, 2026 Galaxy Therapeutics has announced that its SEALâ„¢ Embolization System has received CE Mark certification...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Milpitas, California, August 4, 2026 Galaxy Therapeutics has announced that its SEALâ„¢ Embolization System has received CE Mark certification...
BERLIN, Germany, June 10, 2026 Vara has received CE Class IIb certification under the European Union Medical Device Regulation...
BURLINGTON, Massachusetts, USA, April 28, 2026 SQ Innovation has announced that its drug-device combination therapy Lasix® ONYU has achieved...
Solana Beach, California | January 22, 2026 ClearPoint Neuro has announced the successful EU Medical Device Regulation (EU MDR)...
MINNEAPOLIS, Minnesota — December 15, 2025 — Medical 21, Inc., a privately held medical technology company, announced it has...
